A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
This story was automatically imported from our syndicated feed coverage. Full updates are being tracked closely as more details emerge from local correspondents and global news wires.
Our editorial team is continuously monitoring this topic to bring you the latest developments. Check back regularly for detailed follow-up articles, background analyses, and video broadcasts from the scene.
Reporting sponsored by News Portal Syndicated Coverage.